Gerald E. Quirk - Sep 30, 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal & Compliance Offic
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Sep 30, 2024
Transactions value $
-$6,510
Form type
4
Date filed
10/2/2024, 05:00 PM
Previous filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +10K +25.15% 49.8K Sep 30, 2024 Direct F1
transaction SYRS Common Stock Tax liability -$6.51K -3.1K -6.23% $2.10 46.7K Sep 30, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -10K -33.33% $0.00 20K Sep 30, 2024 Common Stock 10K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding on a restricted stock unit release.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on September 12, 2023. These restricted stock units vested as to one third (1/3rd) of the shares underlying the award on September 30, 2024, and are scheduled to vest as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.